1 August 2024 - The August 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The August issue of the Schedule includes several new/revised listings of note:

• Adalimumab (Humira) - new indication
• Amino acid formula with vitamins and minerals without phenylalanine (PKU Lophlex Select LQ) - new formulation
• Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine (PKU Start) - new formulation
• Atezolizumab (Tecentriq SC) - new formulation
• Beclomethasone dipropionate with eformoterol fumarate dihydrate (Fostair) - new indication
• Cabometinib mesylate (Cabometyx) - new indication
• Elexacaftor with tezacaftor and ivacaftor and ivacaftor (Trikafta) - new indication
• Larotrectinib sulphate (Vitrakvi) - new indication
• Midazolam maleate (Zyamis) - new indication
• Nivolumab (Opdivo) - new indications x 2
• Selumetinib sulphate (Koselugo) - new medicine
• Patisiran sodium (Onpattro) - new gene therapy
• Tadalafil (Tadalis) - restriction change

Read Summary of PBS changes